These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25370152)

  • 1. Novel, high incidence exercise-induced muscle bleeding model in hemophilia B mice: rationale, development and prophylactic intervention.
    Tranholm M; Kristensen AT; Broberg ML; Groth MP
    J Thromb Haemost; 2015 Jan; 13(1):82-91. PubMed ID: 25370152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.
    Toby GG; Liu T; Buyue Y; Zhang X; Bitonti AJ; Pierce GF; Sommer JM; Jiang H; Peters RT
    PLoS One; 2016; 11(2):e0148255. PubMed ID: 26840952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.
    Alamelu J; Bevan D; Sorensen B; Rangarajan S
    J Thromb Haemost; 2014 Dec; 12(12):2044-8. PubMed ID: 25315324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide.
    Østergaard H; Bjelke JR; Hansen L; Petersen LC; Pedersen AA; Elm T; Møller F; Hermit MB; Holm PK; Krogh TN; Petersen JM; Ezban M; Sørensen BB; Andersen MD; Agersø H; Ahmadian H; Balling KW; Christiansen ML; Knobe K; Nichols TC; Bjørn SE; Tranholm M
    Blood; 2011 Aug; 118(8):2333-41. PubMed ID: 21700771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a recombinant factor IX molecule fused to coagulation factor XIII-B subunit.
    Desage S; Leuci A; Enjolras N; Holle LA; Singh S; Delavenne X; Wolberg AS; Biswas A; Dargaud Y
    Haemophilia; 2023 Nov; 29(6):1483-1489. PubMed ID: 37707428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.
    Brinkhous KM; Sigman JL; Read MS; Stewart PF; McCarthy KP; Timony GA; Leppanen SD; Rup BJ; Keith JC; Garzone PD; Schaub RG
    Blood; 1996 Oct; 88(7):2603-10. PubMed ID: 8839853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic administration of glycoPEGylated factor IX provides protection and joint outcome superior to recombinant factor IX after induced joint bleeding.
    Sun J; Livingston EW; Broberg ML; Johansen PB; Ley CD; Knudsen T; Ezban M; Bateman T; Monahan PE; Taves S
    J Thromb Haemost; 2019 Aug; 17(8):1240-1246. PubMed ID: 31148392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged activity of factor IX as a monomeric Fc fusion protein.
    Peters RT; Low SC; Kamphaus GD; Dumont JA; Amari JV; Lu Q; Zarbis-Papastoitsis G; Reidy TJ; Merricks EP; Nichols TC; Bitonti AJ
    Blood; 2010 Mar; 115(10):2057-64. PubMed ID: 20056791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis.
    Sun J; Hua B; Livingston EW; Taves S; Johansen PB; Hoffman M; Ezban M; Monroe DM; Bateman TA; Monahan PE
    Blood; 2017 Apr; 129(15):2161-2171. PubMed ID: 28039188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.
    Perot E; Enjolras N; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y
    Thromb Res; 2015 May; 135(5):1017-24. PubMed ID: 25795563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical safety and efficacy of a new recombinant FIX drug product for treatment of hemophilia B.
    Dietrich B; Schiviz A; Hoellriegl W; Horling F; Benamara K; Rottensteiner H; Turecek PL; Schwarz HP; Scheiflinger F; Muchitsch EM
    Int J Hematol; 2013 Nov; 98(5):525-32. PubMed ID: 24061775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.
    Nummi V; Jouppila A; Lassila R
    Int J Lab Hematol; 2017 Aug; 39(4):359-368. PubMed ID: 28406575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.
    Collins PW; Møss J; Knobe K; Groth A; Colberg T; Watson E
    J Thromb Haemost; 2012 Nov; 10(11):2305-12. PubMed ID: 22998153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.
    Roth DA; Kessler CM; Pasi KJ; Rup B; Courter SG; Tubridy KL;
    Blood; 2001 Dec; 98(13):3600-6. PubMed ID: 11739163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients.
    Preijers T; Hazendonk HCAM; Fijnvandraat K; Leebeek FWG; Cnossen MH; Mathôt RAA
    J Thromb Haemost; 2017 Sep; 15(9):1737-1746. PubMed ID: 28688133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant factor IX (BAX326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial.
    Urasinski T; Stasyshyn O; Andreeva T; Rusen L; Perina FG; Oh MS; Chapman M; Pavlova BG; Valenta-Singer B; Abbuehl BE
    Haemophilia; 2015 Mar; 21(2):196-203. PubMed ID: 25495591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B.
    Windyga J; Abbuehl BE; Hafeman AE
    Expert Rev Hematol; 2014 Jun; 7(3):333-42. PubMed ID: 24832133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX.
    Sun J; Hakobyan N; Valentino LA; Feldman BL; Samulski RJ; Monahan PE
    Blood; 2008 Dec; 112(12):4532-41. PubMed ID: 18716130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of An Orally Effective Factor IX-Transferrin Fusion Protein for Hemophilia B.
    Xie C; Wang Z; Su Y; Wang J; Shen WC
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.